Roivant Sciences (ROIV) President exercises options and sells 1M shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. President & CIO Mayukh Sukhatme reported an exercise-and-sell pattern over two days. On June 25 and 26, he exercised options to acquire a total of 1,000,000 Common Shares at $3.85 per share and sold 1,000,000 Common Shares in open-market transactions.

The sales were executed at weighted average prices of $34.13 and $34.08 per share, each representing multiple trades within disclosed price ranges. Following these transactions, Sukhatme directly held 18,677,617 Common Shares. The underlying options exercised were fully vested and are no longer outstanding.

Insider Trade Summary

Net Seller: 1,000,000 shares ($34,105,000)

Net Sell 6 txns

Insider Sukhatme Mayukh

Role President & CIO

Sold 1,000,000 shs ($34.10M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	500,000	$0.00	--
Exercise	Common Shares	500,000	$3.85	$1.93M
Sale	Common Shares	500,000	$34.08	$17.04M
Exercise	Stock Option (Right to Buy)	500,000	$0.00	--
Exercise	Common Shares	500,000	$3.85	$1.93M
Sale	Common Shares	500,000	$34.13	$17.07M

Holdings After Transaction: Stock Option (Right to Buy) — 14,224,363 shares (Direct, null); Common Shares — 19,177,617 shares (Direct, null)

Footnotes (1)

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Award of stock options to purchase Common Shares that is fully vested.

Key Figures

Shares sold: 1,000,000 Common Shares Options exercised: 1,000,000 shares Exercise price: $3.85 per share +4 more

7 metrics

Shares sold 1,000,000 Common Shares Total open-market sales on June 25–26, 2026

Options exercised 1,000,000 shares Total underlying Common Shares from option exercises

Exercise price $3.85 per share Conversion or exercise price of stock options

Weighted avg sale price 6/25 $34.13 per share Common Shares sold in multiple trades, $33.75–$34.45 range

Weighted avg sale price 6/26 $34.08 per share Common Shares sold in multiple trades, $33.87–$34.67 range

Post-transaction holdings 18,677,617 Common Shares Directly owned after June 26, 2026 transactions

Options exercised per day 500,000 shares Option exercises on each of June 25 and June 26, 2026

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), weighted average price, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale" for non-derivative Common Shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for option-related entries"

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" in derivative records"

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 06:23 PM Accepted by SEC EDGAR 06/29/2026 - 06:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sukhatme Mayukh

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CIO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/25/2026		M		500,000	A	$3.85	19,177,617	D
Common Shares	06/25/2026		S		500,000	D	$34.13(1)	18,677,617	D
Common Shares	06/26/2026		M		500,000	A	$3.85	19,177,617	D
Common Shares	06/26/2026		S		500,000	D	$34.08(2)	18,677,617	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.85	06/25/2026		M			500,000	(3)	04/19/2032	Common Stock	500,000	$0	14,724,363	D
Stock Option (Right to Buy)	$3.85	06/26/2026		M			500,000	(3)	04/19/2032	Common Stock	500,000	$0	14,224,363	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

3. Award of stock options to purchase Common Shares that is fully vested.

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Roivant Sciences (ROIV) report for Mayukh Sukhatme?

Roivant Sciences (ROIV) reported that President & CIO Mayukh Sukhatme exercised options for 1,000,000 Common Shares and sold 1,000,000 Common Shares in open-market transactions on June 25 and 26, 2026, reflecting an exercise-and-sell sequence rather than a simple purchase or sale.

How many Roivant Sciences (ROIV) shares does Mayukh Sukhatme hold after these transactions?

After the reported transactions, Mayukh Sukhatme directly holds 18,677,617 Roivant Sciences (ROIV) Common Shares. This figure reflects his position following the combined option exercises and matching open-market sales completed across June 25 and June 26, 2026, as disclosed in the Form 4 filing.

At what prices did Mayukh Sukhatme sell Roivant Sciences (ROIV) shares?

Mayukh Sukhatme’s Roivant Sciences (ROIV) sales used weighted average prices of $34.13 and $34.08 per share. Footnotes state these averages reflect multiple trades within ranges of $33.75–$34.45 and $33.87–$34.67, with detailed trade breakdowns available on request to relevant parties.

What was the strike price of the Roivant Sciences (ROIV) options exercised?

The options exercised by Mayukh Sukhatme to acquire Roivant Sciences (ROIV) Common Shares had a conversion or exercise price of $3.85 per share. These were fully vested stock options, and the underlying derivative positions were reduced to zero as a result of the exercises.

How many Roivant Sciences (ROIV) options did Mayukh Sukhatme exercise in this filing?

In this filing, Mayukh Sukhatme exercised stock options for a total of 1,000,000 Roivant Sciences (ROIV) Common Shares. The Form 4 shows two derivative transactions, each for 500,000 option shares, both labeled as exercises or conversions of derivative securities into Common Shares.

Was Mayukh Sukhatme’s Roivant Sciences (ROIV) transaction an open-market sale?

Yes. The Form 4 describes the 1,000,000 Roivant Sciences (ROIV) Common Shares disposed as open-market sales. Each non-derivative transaction carries the code “S” and is labeled as a sale in open market or private transaction, executed at disclosed weighted average prices.